Salute e Benessere
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
said Yuling Luo , PhD, Founder, Chairman and CEO of Alamar Biosciences.
As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States , Sweden , United Kingdom , and India . These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium's (GNPC) secure data-sharing processes.
said , Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative.
This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations.
The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at www.alzheimersdata.org .
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com
Logo - https://mma.prnewswire.com/media/1810182/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg
Logo - https://mma.prnewswire.com/media/2707122/Alzheimers_Disease_Data_Initiative_Logo.jpg
Logo - https://mma.prnewswire.com/media/2707123/Gates_Ventures_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alamar-biosciences-alzheimers-disease-data-initiative-and-gates-ventures-unite-in-global-partnership-to-advance-translational-research-in-alzheimers-disease-302477745.html